Catalyst Oncology

Uh-oh, more trouble at t’mill for pharma. Wyeth, a company that comes under the “drugs giant” moniker, has announced it will stop pursuing R&D in eight of its 14 therapeutic areas, and will ‘focus’ on oncology, inflammation, neuroscience, vaccines, metabolic disorders and musculoskeletal disorders. The story hasn’t been posted on Wyeth’s website yet but has hit a number of serious news outfits (Bloomberg, WSJ, Reuters). “This is not a cost-reduction effort at all; the dollars spent and nu

Original post: 
More pharma research cut